{"id":672276,"date":"2026-11-02T02:38:09","date_gmt":"2026-11-02T02:38:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/672276\/"},"modified":"2026-11-02T02:38:09","modified_gmt":"2026-11-02T02:38:09","slug":"veritas-and-travel-iii-laao-with-amulet-360-ttvr-with-lux-valve-plus-system","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/672276\/","title":{"rendered":"VERITAS and TRAVEL III: LAAO With Amulet 360; TTVR With LuX-Valve Plus System"},"content":{"rendered":"

Among patients who underwent left atrial appendage occlusion (LAAO) with the Amulet 360 device, complete LAA closure was observed in 96.3% of patients at one year with low rates of stroke and mortality, according to results from the VERITAS trial, presented at TCT 2026<\/a> and simultaneously published in JACC: Cardiovascular Interventions<\/a>.<\/p>\n

Dhanunjaya Lakkireddy, MD, FACC, et al., included 458 patients (age 74 \u00b1 7.3 years, 38.4% female) with nonvalvular atrial fibrillation and increased thromboembolism risk who underwent LAAO with the Amulet 360 device.<\/p>\n

Using transesophageal echocardiography, complete LAA closure was observed in 96.3% of patients (95% CI, 93.2%-98.2%) at one year post procedure. Clinically relevant device-related thrombosis occurred in 0.4% of patients.<\/p>\n

All-cause mortality was seen in 3.9% of patients, cardiovascular mortality in 1.9%, major bleeding in 6.6%, ischemic stroke or systemic embolism in 1.8%, and pericardial effusion requiring intervention in 0.9%. There were no cases of device embolization.<\/p>\n

“The low mortality observed in VERITAS, together with low rates of pericardial effusion, device embolization, stroke and major bleeding, provides further evidence of a favorable overall clinical profile with the next-generation Amulet 360 device in this pre-market setting,” note Lakkireddy and colleagues.<\/p>\n

Another late-breaking clinical trial, TRAVEL III, found that transjugular transcatheter tricuspid valve replacement (TTVR) with the new LuX-Valve Plus system in addition to optimal medical therapy (OMT) was superior to OMT alone in reducing tricuspid regurgitation (TR).<\/p>\n

Junbo Ge, MD, PhD, FACC, et al., randomized 126 patients with severe or greater TR, NYHA III to IV and of high surgical risk to TTVR with the LuX-Valve Plus system and OMT or OMT alone. The primary safety outcome was a composite of major adverse events at 30 days and the primary efficacy outcome was a composite of survival, freedom from heart failure rehospitalization, TR reduction greater than or equal to one grade and NYHA improvement greater than or equal to one class at six months.<\/p>\n

At six-month follow up, the primary efficacy outcome was observed in 82.9% of patients in the TTVR plus OMT group vs. 4.8% of the OMT only group (rate difference 78.1% [95% CI, 67.5-88.8]; p<0.001).<\/p>\n

Researchers note no incidences of myocardial infarction, stroke, access-site\/vascular complication or device-related pulmonary embolism at six months and low rates of post-procedural pacemaker implantation at 30 days and six months.<\/p>\n

“TRAVEL III provides the first randomized evidence supporting transjugular TTVR with the LuX-Valve Plus system for patients with severe TR at high surgical risk,” states Ge. “TTVR reduced TR in all patients, with less than or equal to moderate TR in 93% at six months.”<\/p>\n


\n Keywords:
\n Transcatheter Cardiovascular Therapeutics, TCT26 \n <\/p>\n","protected":false},"excerpt":{"rendered":"Among patients who underwent left atrial appendage occlusion (LAAO) with the Amulet 360 device, complete LAA closure was…\n","protected":false},"author":2,"featured_media":672277,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-672276","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/672276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=672276"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/672276\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/672277"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=672276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=672276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=672276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}